← All drugs
Drug · FAERS side-effect profile with label screen

Tafenoquine side effects: what 62 FDA adverse event reports show

Tafenoquine · Arakoda · 7 reaction terms · 64 drug–reaction co-reports · data 2026-09-14
Share: X Facebook Reddit Email

Drug class

Antimalarial

FDA label, Indications wording

Brand names

Arakoda

openFDA label

Who reports

62 reports · 89% serious · 4 with death outcome · 20% female

openFDA FAERS counts, all years, deduplication not applied

Used for

ARAKODA is indicated for the prophylaxis of malaria in patients aged 18 years and older. ARAKODA is an antimalarial indicated for the prophylaxis of malaria in patients aged 18 years and older. ( 1 )

FDA label, Indications and Usage

What it is

ARAKODA contains tafenoquine succinate, an antimalarial agent for oral administration.

FDA label, Description section

Boxed warning

None in the current label

How to read this page. FAERS is a spontaneous-reporting system: counts are not incidence rates and a signal is not proof of causation. Each reaction below is run through an automated screen — is the term in the FDA label (known), in the indications (the disease being treated), an administrative/coding term, or none of these (unlabeled)? That screen is mechanical text matching, not a causality assessment. The 30 hand-written Bradford Hill assessments are on the causality assessment page. Not medical advice.

Causality screen of the 6 strongest signals

Labeled adverse reaction 1Reporting / coding artifact 1Not in label — unassessed 4
What the badges mean

Strongest disproportionality signals

Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only and flags pairs whose reports are unusually skewed by sex or come mostly from consumers rather than clinicians. 1 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.

Show:
ReactionReportsPRR 95% CI · ROR · χ²/pEBGM EB05 · IC025Label screenSerious-only & strataTrial cross-check
Brain injury9303.5
165.9–555.5ROR 354.9 · χ² 2,419 / p <1e-300
185.0 EB05 104.2 · IC025 +3.0
3/3 methods agree
Not in label — unassessedserious PRR 199.5no trial data cached
Paranoia10195.4
110.7–344.7ROR 232.7 · χ² 1,745 / p <1e-300
142.7 EB05 82.9 · IC025 +3.2
3/3 methods agree
Not in label — unassessedserious PRR 159.3no trial data cached
Anger14139.5
88.0–221.2ROR 179.9 · χ² 1,791 / p <1e-300
117.5 EB05 74.4 · IC025 +3.7
3/3 methods agree
Not in label — unassessedserious PRR 149.1no trial data cached
Drug resistance8105.4
55.2–201.2ROR 120.8 · χ² 727 / p 2e-160
84.7 EB05 46.0 · IC025 +2.7
3/3 methods agree
Reporting / coding artifactserious PRR 76.9no trial data cached
Mood swings995.4
52.2–174.6ROR 111.5 · χ² 750 / p 2e-165
79.8 EB05 45.0 · IC025 +2.9
3/3 methods agree
Not in label — unassessedserious PRR 108.5no trial data cached
Suicide attempt1055.7
31.6–98.2ROR 66.2 · χ² 485 / p 9e-108
50.6 EB05 29.4 · IC025 +2.9
3/3 methods agree
Labeled adverse reaction
exact term
serious PRR 36.2no trial data cached

Trial evidence (ClinicalTrials.gov)

Trial cross-check not yet run for this drug (ClinicalTrials.gov pull covers the 800 most-reported drugs first).

Most frequently reported reactions

By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.

ReactionReportsPRR 95% CI · ROR · χ²/pEBGM EB05 · IC025Label screenSerious-only & strataTrial cross-check
Anger14139.5
88.0–221.2ROR 179.9 · χ² 1,791 / p <1e-300
117.5 EB05 74.4 · IC025 +3.7
3/3 methods agree
Not in label — unassessedserious PRR 149.1no trial data cached
Suicide attempt1055.7
31.6–98.2ROR 66.2 · χ² 485 / p 9e-108
50.6 EB05 29.4 · IC025 +2.9
3/3 methods agree
Labeled adverse reaction
exact term
serious PRR 36.2no trial data cached
Paranoia10195.4
110.7–344.7ROR 232.7 · χ² 1,745 / p <1e-300
142.7 EB05 82.9 · IC025 +3.2
3/3 methods agree
Not in label — unassessedserious PRR 159.3no trial data cached
Mood swings995.4
52.2–174.6ROR 111.5 · χ² 750 / p 2e-165
79.8 EB05 45.0 · IC025 +2.9
3/3 methods agree
Not in label — unassessedserious PRR 108.5no trial data cached
Brain injury9303.5
165.9–555.5ROR 354.9 · χ² 2,419 / p <1e-300
185.0 EB05 104.2 · IC025 +3.0
3/3 methods agree
Not in label — unassessedserious PRR 199.5no trial data cached
Drug resistance8105.4
55.2–201.2ROR 120.8 · χ² 727 / p 2e-160
84.7 EB05 46.0 · IC025 +2.7
3/3 methods agree
Reporting / coding artifactserious PRR 76.9no trial data cached
Bipolar disorder4123.6
47.9–318.9ROR 132.0 · χ² 372 / p 4e-83
78.6 EB05 32.7 · IC025 +1.3
3/3 methods agree
Not in label — unassessedserious PRR 91.8no trial data cached

Unlabeled candidate signals

Every screened signal with n ≥ 20 was either labeled, an indication term, or an artifact pattern — no unlabeled candidate stood out in the top signals.

Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.

Common questions

What are the most reported side effects of Tafenoquine?

In FDA FAERS, the most frequently co-reported reaction terms for Tafenoquine are anger, suicide attempt, paranoia, mood swings, brain injury, bipolar disorder. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.

Does Tafenoquine have an FDA boxed warning?

No. The FDA label retrieved for Tafenoquine has no boxed warning; see the label's Warnings and Precautions for the recognised risks.

Do FAERS signals prove that Tafenoquine causes these side effects?

No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.

Sources & methods

Page generated 2026-10-08. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.